CRISPR Historical Financial Ratios

CRSP
 Stock
  

USD 60.77  2.23  3.54%   

CRISPR Therapeutics is presently reporting on over 67 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value per Share of 34.09, Current Ratio of 19.3 or Debt to Equity Ratio of 0.16 will help investors to properly organize and evaluate CRISPR Therapeutics financial condition quickly. Financial Statement Analysis is way more than just reviewing and evaluating CRISPR Therapeutics prevailing accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether CRISPR Therapeutics is a good buy for the upcoming year.
Continue to Trending Equities.
  
Refresh

About CRISPR Financial Ratios Analysis

CRISPR TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate CRISPR Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on CRISPR financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across CRISPR Therapeutics history.

CRISPR Therapeutics Financial Ratios Chart

CRISPR Therapeutics AG financial ratios usually calculated using numerical values taken directly from CRISPR Therapeutics financial statements such as income statements or balance sheets. They help investors to obtain meaningful information about CRISPR Therapeutics. Most financial ratios help to conduct quantitative analysis to assess vital information about the company's valuation as well as profitability and liquidity indicators such as leverage, growth, profit margins, and different types of rates of return.
CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 30th of June 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.

Asset Turnover

Asset turnover is a measure of a firms operating efficiency; calculated by dividing Revenues by Average Assets. Often a component of DuPont ROE analysis.

Return on Average Assets

Return on assets measures how profitable a company is Net Income Common Stock relative to its total assets [AssetsAvg].

Return on Average Equity

Return on equity measures a corporation's profitability by calculating the amount of Net Income Common Stock returned as a percentage of [EquityAvg].

Return on Sales

Return on Sales is a ratio to evaluate a company's operational efficiency; calculated by dividing Earning Before Interest and Taxes EBIT by Revenues. ROS is often a component of DuPont ROE analysis.
Most ratios from CRISPR Therapeutics fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into CRISPR Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Continue to Trending Equities.CRISPR Therapeutics Enterprise Value over EBIT is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Enterprise Value over EBIT of 13.00. As of 30th of June 2022, Enterprise Value over EBITDA is likely to grow to 13.50, while Current Ratio is likely to drop 19.30.

CRISPR Therapeutics fundamentals Correlations

0.70.580.270.250.520.510.930.920.43-0.710.3-0.310.88-0.20.93-0.390.280.460.89
0.70.750.460.120.210.190.660.670.14-0.730.170.030.420.330.83-0.710.140.00.78
0.580.750.06-0.13-0.29-0.310.670.690.35-0.45-0.080.210.350.260.6-0.83-0.150.070.54
0.270.460.06-0.10.360.360.330.34-0.69-0.17-0.080.140.150.10.3-0.51-0.120.090.22
0.250.12-0.13-0.10.340.34-0.06-0.080.18-0.191.00.010.130.10.370.320.99-0.10.23
0.520.21-0.290.360.341.00.30.290.16-0.620.34-0.670.5-0.50.510.310.390.490.63
0.510.19-0.310.360.341.00.290.280.15-0.60.34-0.670.49-0.50.490.320.390.490.61
0.930.660.670.33-0.060.30.291.00.3-0.54-0.01-0.150.86-0.10.79-0.57-0.040.380.74
0.920.670.690.34-0.080.290.281.00.29-0.55-0.02-0.140.84-0.080.78-0.59-0.060.370.75
0.430.140.35-0.690.180.160.150.30.29-0.550.19-0.460.38-0.290.380.210.220.280.54
-0.71-0.73-0.45-0.17-0.19-0.62-0.6-0.54-0.55-0.55-0.220.45-0.430.13-0.770.22-0.22-0.31-0.95
0.30.17-0.08-0.081.00.340.34-0.01-0.020.19-0.220.030.160.120.410.280.98-0.10.27
-0.310.030.210.140.01-0.67-0.67-0.15-0.14-0.460.450.03-0.490.82-0.34-0.4-0.09-0.75-0.44
0.880.420.350.150.130.50.490.860.840.38-0.430.16-0.49-0.390.78-0.170.20.560.67
-0.20.330.260.10.1-0.5-0.5-0.1-0.08-0.290.130.120.82-0.39-0.12-0.330.06-0.93-0.17
0.930.830.60.30.370.510.490.790.780.38-0.770.41-0.340.78-0.12-0.420.410.40.9
-0.39-0.71-0.83-0.510.320.310.32-0.57-0.590.210.220.28-0.4-0.17-0.33-0.420.36-0.02-0.3
0.280.14-0.15-0.120.990.390.39-0.04-0.060.22-0.220.98-0.090.20.060.410.36-0.070.27
0.460.00.070.09-0.10.490.490.380.370.28-0.31-0.1-0.750.56-0.930.4-0.02-0.070.39
0.890.780.540.220.230.630.610.740.750.54-0.950.27-0.440.67-0.170.9-0.30.270.39
Click cells to compare fundamentals

CRISPR Therapeutics Account Relationship Matchups

CRISPR Therapeutics fundamentals Accounts

201720182019202020212022 (projected)
Asset Turnover0.140.0070.420.0010.350.38
Book Value per Share4.698.1817.2725.2431.5934.09
Current Ratio17.1216.8117.2918.2120.1719.3
Debt to Equity Ratio0.450.250.140.0980.150.16
EBITDA Margin(1.55)(51.51)0.250.430.50.54
Earnings per Basic Share(1.71)(3.44)1.23(5.29)4.975.36
Earnings per Diluted Share(1.71)(3.44)1.17(5.29)4.75.07
Earnings per Basic Share USD(1.71)(3.44)1.23(5.29)4.975.36
Enterprise Value over EBIT(11.0)(6.0)41.0(28.0)13.014.03
Enterprise Value over EBITDA(11.11)(6.17)38.46(28.94)12.5213.5
Free Cash Flow per Share(1.94)(2.06)0.92(3.89)6.026.5
Profit Margin(1.67)(52.81)0.230.410.470.51
Price to Book Value5.133.783.586.52.423.01
Price to Earnings Ratio(13.73)(8.3)49.52(28.94)15.2516.45
Price to Sales Ratio22.94438.6511.4414.04 K6.296.46
Return on Average Assets(0.23)(0.38)0.096(0.26)0.140.16
Return on Average Equity(0.35)(0.48)0.12(0.29)0.160.17
Return on Invested Capital(5.01)(28.28)0.9(1.18)0.260.28
Return on Sales(1.62)(52.63)0.23(484.08)0.420.45
Sales per Share1.020.0655.320.01112.0513.0
Tangible Assets Book Value per Share6.7710.1919.6127.7236.2330.69

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Correlation Analysis Now

   

Correlation Analysis

Reduce portfolio risk simply by holding instruments which are not perfectly correlated
All  Next Launch Module
Continue to Trending Equities. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.